Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
Completed · Phase 2 · Has a placebo group
Conditions studied: Metastatic Cancer, Prostate Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining docetaxel with imatinib mesylate may be effective treatment for androgen-independent prostate cancer and bone metastases. PURPOSE: This randomized phase II trial is studying docetaxel and imatinib mesylate to see how well they work compared to docetaxel alone in treating patients with androgen-independent prostate cancer and bone metastases.
Key facts
- Study ID
- NCT00080678
- Run by
- M.D. Anderson Cancer Center
- People needed
- 116
- Starts
- 2003-05-01
- Expected to finish
- 2008-03-01
- Last updated by the study team
- 2012-10-12
Who can join
Age: any. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- M.D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.